Bausch Health Companies Inc. (TSE:BHC - Get Free Report) was down 1.4% during trading on Monday . The company traded as low as C$7.70 and last traded at C$8.01. Approximately 746,307 shares were traded during mid-day trading, an increase of 109% from the average daily volume of 356,868 shares. The stock had previously closed at C$8.12.
Bausch Health Companies Price Performance
The firm has a market capitalization of C$2.08 billion, a P/E ratio of -11.72, a P/E/G ratio of 0.21 and a beta of 0.77. The business's fifty day moving average is C$6.74 and its 200 day moving average is C$9.08. The company has a current ratio of 1.19, a quick ratio of 0.58 and a debt-to-equity ratio of -1,831.94.
Insiders Place Their Bets
In related news, Director John Paulson purchased 502,688 shares of the firm's stock in a transaction that occurred on Thursday, June 12th. The stock was acquired at an average price of C$7.44 per share, for a total transaction of C$3,739,596.57. Over the last 90 days, insiders have acquired 1,771,371 shares of company stock worth $12,585,871. 11.28% of the stock is owned by insiders.
Bausch Health Companies Company Profile
(
Get Free Report)
Bausch Health Companies Inc operates as a diversified specialty pharmaceutical and medical device company in the United States and internationally. It develops, manufactures, and markets a range of products primarily in gastroenterology, hepatology, neurology, dermatology, international pharmaceuticals, over-the-counter (OTC) products, aesthetic medical devices, and eye health.
See Also
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Bausch Health Companies, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Bausch Health Companies wasn't on the list.
While Bausch Health Companies currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Which stocks are hedge funds and endowments buying in today's market? Enter your email address and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying now.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
